Article Document Academic Article Information Content Entity Continuant Continuant Journal Article Entity Entity Generically Dependent Continuant 2025-06-26T10:52:58 RDF description of Blood outgrowth endothelial cells as a cellular carrier for oncolytic vesicular stomatitis virus expressing Interferon-β in preclinical models of non-small cell lung cancer - http://repository.healthpartners.com/individual/document-rn21142 Lung Cancer 10.1016/j.tranon.2020.100782 public <p>Oncolytic viruses have demonstrated efficacy in numerous tumor models including non-small cell lung cancer (NSCLC). One limitation of viral therapy for metastatic lung cancer is that systemic administration can be hindered by complement and antiviral immunity. Thus, we investigated whether ex vivo-infected blood outgrowth endothelial cells (BOECs) could be used to deliver VSV-IFNβ in preclinical models of NSCLC. BOECs were obtained from human donors or C57/Bl6 mice. VSV was engineered to produce GFP or IFNβ. Human and murine BOECs could be infected by VSV-GFP and VSV-IFNβ. Infected BOECs resulted in killing of NSCLC cells in vitro and shielded VSV-IFNβ from antibody neutralization. Mouse BOECs localized to lungs of mice bearing syngeneic LM2 lung tumors, and infected murine BOECs reduced tumor burden in this model. In an immune-deficient A549 xenograft model, mice treated with VSV-IFNβ-infected human BOECs exhibited superior antitumor activity and survival of mice (n�=�10, P�<�.05 compared to VSV-IFNβ alone). We conclude that BOECs can be used as a carrier for delivery of oncolytic VSV-IFNβ. This may be an effective strategy for clinical translation of oncolytic virotherapy for patients with metastatic NSCLC.<p> 13 28184 16832 Translational Oncology 2022-02-21T22:48:57.408-06:00 7 Animal Studies document-rn21142 Drugs and Drug Therapy Blood outgrowth endothelial cells as a cellular carrier for oncolytic vesicular stomatitis virus expressing Interferon-β in preclinical models of non-small cell lung cancer